BPC-157

BPC-157 is a stable peptide — a chain of 15 amino acids.

It was not designed in a lab from scratch.

It copies a fragment of a protein found naturally in human gastric juice.

Its main action is on blood vessels.

It supports the formation of new microvessels and regulates nitric oxide — the molecule that relaxes their walls.

More vessels means more blood, oxygen and nutrients at the spot that needs repair.

The rest is built on that base: collagen, fibroblasts, healing.

Unlike many molecules, studies report very few adverse effects.

This unusually 'quiet' profile is one reason it draws attention.

Still, it remains a research compound. It has not been approved as a medicine.

For years the data were almost entirely in animals. In 2026 something shifted.

In rings of human mammary artery, the peptide produced endothelium-mediated relaxation of the vessel — the first functional evidence in human arterial tissue.

BPC-157, TB-500 and GHK-Cu turn up together in searches, but they belong to different families and are studied for different things.

BPC-157 is a pentadecapeptide of 15 amino acids, ≈1419 Da, derived from a fragment of a human gastric protein. Research focuses on blood vessels — angiogenesis and the nitric oxide pathway.

TB-500 is a synthetic fragment of thymosin β4, ≈889 Da. Research focuses on actin regulation and cell motility.

GHK-Cu is a copper-binding tripeptide, ≈340 Da, a naturally occurring plasma complex. Research focuses on skin and collagen synthesis.

The substantive difference: BPC-157 is studied in relation to the route that delivers blood and oxygen; TB-500 in relation to the cell's internal scaffolding; GHK-Cu in relation to the material built around cells. Different points in the same process — which is why the first two are often studied together.

Fields of research — not a promise of outcome. None of the three is approved as a medicine.

The literature is not uniform. It divides into distinct lines of research that are frequently presented as if they were one.

Musculoskeletal tissue. The largest line. A 2025 systematic review identified 544 papers from 1993 to 2024 and included 36 after screening. In preclinical models it recorded improvements in functional, structural and biomechanical measures across muscle, tendon, ligament and bone, alongside increased growth hormone receptor expression and reduced inflammatory cytokines.

The vascular mechanism — why everything converges here. Activation of the VEGFR2 receptor and nitric oxide synthesis via the Akt–eNOS axis, with ERK1/2 signalling. The described result is angiogenesis, fibroblast activity and neuromuscular stabilisation, particularly in poorly vascularised tissue such as tendons and myotendinous junctions. This explains why one molecule appears across such different fields: the common denominator is the blood vessel.

Digestive tract. A separate line, with a history predating the sports medicine interest. It examines stabilisation of intestinal epithelial permeability and cytoprotection against damage from non-steroidal anti-inflammatory drugs.

Nervous system. The newest and least mature line, in preclinical models, emphasising the relationship with the nitric oxide system.

Stability of the molecule. It remains intact for more than 24 hours in human gastric juice, where most peptides degrade rapidly in an acidic environment.

Of the 36 studies included in the 2025 systematic review, 35 were preclinical and one was clinical.

The same literature that assembles the positive findings concludes that only three pilot studies have examined the molecule in humans, and that it should be considered investigational until well-designed clinical trials are conducted.

Human research is at an early stage and the studies are small. There are no large-scale clinical safety data.

This is not a footnote. It is the frame within which everything above is read.

BPC-157 holds no marketing authorisation from the Greek EOF, the EMA or the FDA. Nor is it a prohibited substance. It sits in a transitional regulatory position and is supplied as laboratory research material.

What changed in 2026. In April it was removed from the FDA's Category 2. In July the PCAC committee voted 8–6 in favour of its inclusion in 503A compounding. A final decision is pending.

Pages can be found calling it approved and others calling it banned. Both are wrong.

In practice. It is supplied lawfully as research material. It is not available in pharmacies, is not prescribed, and is not reimbursed.

Shipping. Avenor ships from Greece. No customs step is involved and delivery times are domestic, unlike orders placed from third countries.

A Certificate of Analysis is the only document that connects a specific vial to an actual laboratory measurement.

A batch number that matches the product. The most important element, and the one most often missing. A COA with no batch number — or with a number that does not appear on the product — verifies nothing.

Identity of the molecule, not only purity. Purity states that 99% of the contents is a single substance. It does not state which one. Identity is established by mass spectrometry, which measures molecular weight — for BPC-157, approximately 1419 Da.

Method of measurement. Typically HPLC for purity and mass spectrometry for identity. A figure without a method is not verifiable.

Date and laboratory. An analysis without a date does not correspond to a batch.

And one thing that must not appear: any medical indication, condition or promise of outcome. If a COA carries them, that is not a sign of rigour — it is a red flag, because the document was written to sell rather than to measure.

Avenor's position. Where a COA exists it is published and linked to the SKU. Where none exists, this is stated explicitly. Not every batch carries an analysis, and we say so rather than leaving it ambiguous.

1990s — isolated from human gastric juice; first papers from 1993.

2015 — Phase 1 begins in humans, 42 healthy volunteers (NCT02637284).

2016 — Phase 1 completes.

2020–2022 — reviews covering intestinal permeability, the nervous system and the vascular mechanism.

April 2026 — removed from the FDA's Category 2.

July 2026 — PCAC votes 8–6 in favour of 503A compounding.

Today — Phase 2 under way: 120 participants, randomised, double-blind, placebo-controlled (NCT07437547).

226 published papers on PubMed, and just three pilot studies in humans. Both figures are true at once.